Clinical trials: Plasma Cell Tumor
Multiple Myeloma
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past.
- Trial name
- NCT01602224
- Testing
- Dexamethasone, Bortezomib, Tabalumab
- Where
- 57 sites in United States, Brazil and 13 more
- Volunteers
- 220 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
This observational study will observe the degree of the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of…
- Trial name
- NCT01021592
- Testing
- bortezomib
- Volunteers
- 140 people
- Sponsor
- Janssen Korea, Ltd., Korea
Amyloidosis; Systemic
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.
- Trial name
- AT03-001 (NCT05201911)
- Testing
- 124I-AT03
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Attralus, Inc.
Relapsed/Refractory B-cell Malignancies
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: Identify the recommended dose of AC676 that can be given safely to…
- Trial name
- NCT05780034
- Testing
- AC676
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Accutar Biotechnology Inc
Multiple Myeloma
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with…
- Trial name
- DREAMM 7 (NCT06868667)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 16 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi
Multiple Myeloma
Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to investigate the anti-myeloma effect of panobinostat given at two different doses (10 mg and 20 mg oral) in combination with carfilzomib (20/56 mg/m2 i.v.) and low dose dexamethasone (20 mg oral) vs…
- Trial name
- PANORAMA-5 (NCT02756663)
- Testing
- panobinostat (capsules), carfilzomib (infusion), dexamethasone (tablets)
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Myeloma Multiple
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell
- Trial name
- NCT04782687
- Testing
- Selinexor, Dexamethasone Oral, Daratumumab
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- US Oncology Research
Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone…
- Trial name
- NCT00622336
- Testing
- CC-5013, Lenalidomide
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 330 people
- Sponsor
- Celgene
Multiple Myeloma, Non-Hodgkin's Lymphoma
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib).
- Trial name
- NCT00608907
- Testing
- bortezomib, bortezomib, rifampicin, bortezomib, dexamethasone
- Where
- 9 sites in Israel, Italy and 3 more
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing…
- Trial name
- MagnetisMM-7 (NCT05317416)
- Testing
- Elranatamab, Lenalidomide
- Where
- 209 sites in United States, Australia and 25 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Osteopenia, Osteoporosis
FREE Study - Fracture Reduction Evaluation
The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral body compression fractures.
- Conditions
- Osteopenia, Osteoporosis, Multiple Myeloma, Bone Neoplasms
- Trial name
- NCT00211211
- Testing
- Balloon Kyphoplasty
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Medtronic Spine LLC
Relapsed Multiple Myeloma, End-stage Renal Disease
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing.
- Trial name
- NCT01949532
- Testing
- Carfilzomib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Amgen
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in…
- Trial name
- NCT04434469
- Testing
- RO7297089
- Where
- 10 sites in Australia, Belgium and 2 more
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Multiple Myeloma
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM)…
- Trial name
- ABE-DESCART (NCT06154902)
- Testing
- Idecabtagene vicleucel, Not treated
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia, Lymphoma
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT05618041
- Testing
- CAR-T Autologous T cell injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor…
- Trial name
- NCT04318327
- Testing
- PHE885
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
B-Cell Chronic Lymphocytic Leukemia
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
The purpose of this study is to assess the effect of a moderate Cytochrome P450 (CYP) 3A inhibitor (erythromycin) and a strong CYP3A inhibitor (voriconazole) on the steady-state pharmacokinetics (PK [the study of the way a drug…
- Trial name
- NCT02381080
- Testing
- Ibrutinib, Erythromycin, Voriconazole
- Where
- 6 sites in Canada, Russia and 1 more
- Volunteers
- 26 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers…
- Trial name
- THINK (NCT03018405)
- Testing
- NKR-2 cells
- Where
- 5 sites in United States, Belgium
- Volunteers
- 146 people
- Sponsor
- Celyad Oncology SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.